Last updated on May 2018

Autologous Dendritic Cell Vaccination in Mesothelioma


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Malignant Pleural Mesothelioma
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Diagnosis with histologically proven epithelial
  • Aged 18 years at the time of enrollment
  • WHO performance status 0-1 at the time of enrollment
  • Fit to undergo general anesthesia, a thoracoscopy, leukapheresis, chemotherapy, immunotherapy and P/D (in case of resectable disease)
  • No history of receiving any investigational treatment within 28 days of study enrollment
  • No history of intolerance to pemetrexed and/or cisplatin
  • Women of child bearing potential must have negative serum or urine pregnancy test within 72 hours prior to the first dose of study treatment/surgery. They should use adequate birth control measures, as defined by the investigator, during the study treatment period and for at least three months after the last study treatment. Female subjects who are breastfeeding should discontinue nursing prior to the first dose of study treatment and until three months after the last study treatment
  • Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discusses with the patient before registration in the trial. Absence of any other inability or unwillingness to comply with the requirements of the protocol as assessed by the investigator
  • Before patient registration written informed consent must be given according to ICH/GCP, and national/local regulations

Exclusion Criteria:

  • Unwilling or unable to comply with the study requirements
  • Prior treatment for MPM
  • History of another malignancy within the last five years (except for carcinoma in situ of the cervix, basal cell or spinocellular carcinoma of the skin or unless the investigator rationalizes otherwise)
  • Known proven metastases
  • Known concomitant presence of any immunosuppressive disease (e.g. HIV) or any active autoimmune condition, except for vitiligo
  • Pregnant or breast-feeding

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.